TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
C Guillerey, H Harjunpää, N Carrié… - Blood, The Journal …, 2018 - ashpublications.org
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so
far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven …
far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven …
[HTML][HTML] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
KL Banta, X Xu, AS Chitre, A Au-Yeung, C Takahashi… - Immunity, 2022 - cell.com
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
Implications of PD-1, Tim-3, and TIGIT expression for cancer immunity and pancreatic cancer prognosis
C Nakayama, K Tanoue, T Idichi… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: The development and application of cancer immunotherapy to pancreatic
cancer has not progressed because its efficacy has not been proven in clinical trials. In this …
cancer has not progressed because its efficacy has not been proven in clinical trials. In this …
[HTML][HTML] TIGIT-CD155 interactions in melanoma: a novel co-inhibitory pathway with potential for clinical intervention
K Mahnke, AH Enk - Journal of Investigative Dermatology, 2016 - Elsevier
Inozume et al. describe a novel immunosuppressive mechanism in melanoma that is
triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and …
triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and …
T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer
M Fathi, I Pustokhina, SV Kuznetsov, M Khayrullin… - IUBMB …, 2021 - Wiley Online Library
The importance of the tumor microenvironment in cancer progression has been well studied
for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in …
for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in …
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
K Hansen, S Kumar, K Logronio, S Whelan… - Cancer Immunology …, 2021 - Springer
Immune checkpoint inhibitors (ICIs) have emerged as promising therapies for the treatment
of cancer. However, existing ICIs, namely PD-(L) 1 and CTLA-4 inhibitors, generate durable …
of cancer. However, existing ICIs, namely PD-(L) 1 and CTLA-4 inhibitors, generate durable …
[HTML][HTML] TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
S Kawashima, T Inozume, M Kawazu… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Patients with cancer benefit from treatment with immune checkpoint inhibitors
(ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor …
(ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor …
[HTML][HTML] The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
F Arruga, M Rubin, D Papazoglou, A Iannello… - …, 2023 - ncbi.nlm.nih.gov
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory checkpoint receptor
that negatively regulates T-cell responses. CD226 competes with TIGIT for binding to the …
that negatively regulates T-cell responses. CD226 competes with TIGIT for binding to the …
Immune checkpoint molecule TIGIT manipulates T cell dysfunction in septic patients
Y Sun, R Ding, Y Chang, J Li, X Ma - International immunopharmacology, 2021 - Elsevier
Sepsis is a dysregulated host response to infection. T cell dysfunction results in the failure to
eradicate pathogens and the increased susceptibility to nosocomial infections and mortality …
eradicate pathogens and the increased susceptibility to nosocomial infections and mortality …
TIGIT axis: novel immune checkpoints in anti-leukemia immunity
D Qiu, X Liu, W Wang, X Jiang, X Wu, J Zheng… - Clinical and …, 2023 - Springer
Hematologic malignancy evades immune-mediated recognition through upregulating
various checkpoint inhibitory receptors (IRs) on several types of lymphocytes …
various checkpoint inhibitory receptors (IRs) on several types of lymphocytes …